Treating patients with renal cell carcinoma and bone metastases.
Bone metastases (BMs) are common and cause morbidity in cancer patients. This review focuses on evidence in BMs from metastatic renal cell carcinoma (mRCC) management and discusses current evidence on the role of systemic treatments in BMs management, bone-targeting agents' benefits in skeletal-related events prevention and local therapeutic approaches to BM in mRCC. Areas covered: A comprehensive review of literature concerning incidence, prognosis, and therapeutic approaches of BMs was performed, focusing on the latest emerging evidence in management of BMs from mRCC. Expert commentary: One-third of mRCC patients present metastatic disease to the bone. BMs impact negatively the prognosis and decrease quality of life. Adequate management of BMs from RCC requires a multimodal evaluation to optimize care and quality of life. Both tyrosine-kinase inhibitors and immunotherapy may be effective in BMs treatment. BMs cause severe complications such as fracture, spinal cord compression, and pain requiring surgery or radiotherapy and several local approaches are available to achieve a local control of the disease. Defining prognosis of systemic disease and identifying the main goal of treatment is crucial for the selection of the best strategy.
['Guida|Annalisa|A|', 'Escudier|Bernard|B|', 'Albiges|Laurence|L|']
D001859:Bone Neoplasms D002292:Carcinoma, Renal Cell D003131:Combined Modality Therapy D006801:Humans D007167:Immunotherapy D007680:Kidney Neoplasms D011379:Prognosis D047428:Protein Kinase Inhibitors D011788:Quality of Life
bone metastases Mrcc systemic treatments bone target agents local treatment